ATE84540T1 - Methode zur foerderung einer disulfidverbindung in rekombinanten proteinen und formulationen, welche diese produkte enthalten. - Google Patents

Methode zur foerderung einer disulfidverbindung in rekombinanten proteinen und formulationen, welche diese produkte enthalten.

Info

Publication number
ATE84540T1
ATE84540T1 AT85308265T AT85308265T ATE84540T1 AT E84540 T1 ATE84540 T1 AT E84540T1 AT 85308265 T AT85308265 T AT 85308265T AT 85308265 T AT85308265 T AT 85308265T AT E84540 T1 ATE84540 T1 AT E84540T1
Authority
AT
Austria
Prior art keywords
sup
recombinant proteins
products
promoting
sub
Prior art date
Application number
AT85308265T
Other languages
English (en)
Inventor
Kirston Edward Koths
Robert Forgan Halenbeck
Original Assignee
Cetus Oncology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24725645&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE84540(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cetus Oncology Corp filed Critical Cetus Oncology Corp
Application granted granted Critical
Publication of ATE84540T1 publication Critical patent/ATE84540T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/811—Interferon

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AT85308265T 1984-12-06 1985-11-13 Methode zur foerderung einer disulfidverbindung in rekombinanten proteinen und formulationen, welche diese produkte enthalten. ATE84540T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/679,121 US4572798A (en) 1984-12-06 1984-12-06 Method for promoting disulfide bond formation in recombinant proteins
EP85308265A EP0185459B1 (de) 1984-12-06 1985-11-13 Methode zur Förderung einer Disulfidverbindung in rekombinanten Proteinen und Formulationen, welche diese Produkte enthalten

Publications (1)

Publication Number Publication Date
ATE84540T1 true ATE84540T1 (de) 1993-01-15

Family

ID=24725645

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85308265T ATE84540T1 (de) 1984-12-06 1985-11-13 Methode zur foerderung einer disulfidverbindung in rekombinanten proteinen und formulationen, welche diese produkte enthalten.

Country Status (13)

Country Link
US (1) US4572798A (de)
EP (1) EP0185459B1 (de)
JP (1) JPH0696600B2 (de)
KR (1) KR940003475B1 (de)
AT (1) ATE84540T1 (de)
AU (1) AU594930B2 (de)
BR (1) BR8506101A (de)
CA (1) CA1248300A (de)
DE (1) DE3586987T2 (de)
ES (1) ES8700271A1 (de)
GB (1) GB2168055B (de)
IN (1) IN163025B (de)
ZA (1) ZA859001B (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925919A (en) * 1984-04-25 1990-05-15 Roland Mertelsmann Purified interleukin 2
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
EP0158487B1 (de) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stabile Interleukin-2-Zusammensetzung
US4908434A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Process for preparing purified interleukin-2
US4908433A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
GB8508340D0 (en) * 1985-03-29 1985-05-09 Creighton T E Production of protein
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
DE3621828A1 (de) * 1986-06-28 1988-01-14 Biotest Pharma Gmbh Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
US4683293A (en) * 1986-10-20 1987-07-28 Phillips Petroleum Company Purification of pichia produced lipophilic proteins
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
CA1339757C (en) * 1987-04-16 1998-03-17 Robert F. Halenbeck Production of purified biologically active, bacterially produced recombinant human csf-1
AU622860B2 (en) * 1987-05-11 1992-04-30 Novartis Vaccines And Diagnostics, Inc. Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
US4961969A (en) * 1987-05-11 1990-10-09 Cetus Corporation Process for recovering microbially produced interferon-β
US4801691A (en) * 1987-05-15 1989-01-31 International Minerals & Chemical Corp. Method for removing sodium dodecyl sulfate from sodium dodecyl sulfate solubilized protein solutions
JP2669859B2 (ja) * 1987-08-04 1997-10-29 協和醗酵工業株式会社 タンパク質の再活性化法
US5759815A (en) * 1988-02-11 1998-06-02 Creative Biomolecules, Inc. Production of platelet derived growth factor (PDGF) an muteins thereof
CA1340586C (en) * 1988-09-23 1999-06-08 Cetus Corporation Process for recovering microbially produced interferon-beta
JP2517100B2 (ja) * 1989-03-08 1996-07-24 協和醗酵工業株式会社 ヒト顆粒球コロニ―刺激因子活性を有する蛋白質の精製法
US5204256A (en) * 1989-09-06 1993-04-20 Behringwerke Aktiengesellschaft Process for the purification of plasminogen activator inhibitor 2 (pai-2)
CA2070393A1 (en) * 1989-10-18 1991-04-19 Charles M. Cohen Biosynthetic constructs of tgf-beta
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
DE69031596T2 (de) * 1990-11-23 1998-02-26 Roussel Uclaf Verfahren zur herstellung eines proteins gehörend zu der klasse der cytokine, das mindestens eine intramolekulare disulfidbrücke enthält, durch oxidation bei einem ph-wert kleiner als 5.0 des entsprechenden rekombinanten reduzierten proteins
IT1245063B (it) * 1991-04-12 1994-09-13 Ferruzzi Ricerca & Tec Procedimento per l'ossidazione di carboidrati
US5466781A (en) * 1991-05-24 1995-11-14 Chiron Therapeutics Process for purifying bacterially produced M-CSF
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
FR2684878B1 (fr) * 1991-12-12 1994-02-11 Roussel Uclaf Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
US20030171292A1 (en) * 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
CA2147466A1 (en) * 1992-10-20 1994-04-28 Just P. J. Brakenhoff Interleukin-6 receptor antagonists
US5661001A (en) * 1993-08-04 1997-08-26 Ciba-Geigy Corporation High molecular weight desulphatohirudin
US5663304A (en) * 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
TW517059B (en) 1994-07-25 2003-01-11 Ciba Geigy Ag New process for the production of biologically active protein
DE19547933A1 (de) * 1995-12-22 1997-06-26 Boehringer Mannheim Gmbh Multimere Formen von IL-16, Verfahren zu ihrer Herstellung und Verwendung
AU735459B2 (en) 1997-01-30 2001-07-12 University Of Virginia Patent Foundation Cysteine-depleted peptides recognized by A3-restricted cytotoxic lymphocytes, and uses therefor
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7270809B2 (en) 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
CN1269805A (zh) 1997-07-14 2000-10-11 博尔德生物技术公司 生长激素和相关蛋白的衍生物
GB9806632D0 (en) * 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
JP2002534119A (ja) * 1999-01-14 2002-10-15 ボルダー バイオテクノロジー， インコーポレイテッド 自由システイン残基を有するタンパク質の生産方法
US6808902B1 (en) * 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
EP1935431A3 (de) 2000-05-15 2008-08-13 Health Research, Inc. Krebsbehandlungen unter Verwendung einer Kombination aus einem HER2-Antikörper und Interleukin-2
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
IL161407A0 (en) * 2001-10-15 2004-09-27 Chiron Corp Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
WO2005016371A1 (en) 2003-07-11 2005-02-24 Schering Aktiengesellschaft IMPROVED RECOMBINANT HUMAN INTERFERON-BETA-1b POLYPEPTIDES
JP4746552B2 (ja) 2003-11-04 2011-08-10 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 自己免疫疾患および炎症性疾患ならびに臓器移植拒絶の処置のためのアンタゴニスト抗ｃｄ４０抗体の使用
WO2005110059A2 (en) * 2004-03-17 2005-11-24 Chiron Corporation Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi)
HUE037162T2 (hu) 2007-07-09 2018-08-28 Genentech Inc Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
US8273561B2 (en) * 2007-10-05 2012-09-25 Nuron Biotech, Inc. High pressure treatment of aggregated interferons
HUE053480T2 (hu) 2009-04-30 2021-06-28 Ablynx Nv Eljárás domén ellenanyagok elõállítására
KR101741859B1 (ko) 2009-06-22 2017-06-15 암젠 인크 화학적으로 조절된 산화환원 상태를 사용한 단백질의 재폴딩
SI3660032T1 (sl) 2009-06-25 2026-02-27 Amgen Inc. Postopki zajemanja in čiščenja beljakovin, izraženih v nesesalskem sistemu
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
GB201101794D0 (en) * 2011-02-02 2011-03-16 Fermentas Uab Protein production
US10781242B2 (en) 2013-09-24 2020-09-22 Medicenna Therapeutics Inc. Interleukin-2 fusion proteins and uses thereof
US10150802B2 (en) 2014-04-24 2018-12-11 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
US10806773B2 (en) 2014-10-09 2020-10-20 Dana-Farber Cancer Institute, Inc. Multiple-variable IL-2 dose regimen for treating immune disorders
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
JP7433051B2 (ja) 2017-06-19 2024-02-19 メディシナ セラピューティクス インコーポレイテッド Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法
PH12020550661A1 (en) 2017-11-21 2021-04-19 Univ Leland Stanford Junior Partial agonists of interleukin-2
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
SG11202008979QA (en) * 2018-03-28 2020-10-29 Two Tag Holdings Pty Ltd Methods for measuring relative oxidation levels of a protein
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
EP4090674A4 (de) 2020-01-14 2024-01-24 Synthekine, Inc. Vorgespannte il2-muteins-verfahren und -zusammensetzungen
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450103A (en) * 1982-03-01 1984-05-22 Cetus Corporation Process for recovering human IFN-β from a transformed microorganism
JPS5927858A (ja) * 1982-08-05 1984-02-14 Nippon Shinyaku Co Ltd ポリペプチドの製法
US4490289A (en) * 1982-09-16 1984-12-25 Hoffmann-La Roche Inc. Homogeneous human interleukin 2
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
FI82266C (fi) * 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
IL90047A (en) * 1982-10-19 1992-12-01 Cetus Oncology Corp Cysteine-depleted biologically active muteins other than interferon - '
IE56372B1 (en) * 1982-12-22 1991-07-03 Genentech Inc Microbially produced rennet methods for its production and plasmids used for its production
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins

Also Published As

Publication number Publication date
ES549135A0 (es) 1986-09-01
ES8700271A1 (es) 1986-09-01
GB8528017D0 (en) 1985-12-18
BR8506101A (pt) 1986-08-19
EP0185459B1 (de) 1993-01-13
GB2168055A (en) 1986-06-11
EP0185459A2 (de) 1986-06-25
ZA859001B (en) 1986-08-27
CA1248300A (en) 1989-01-03
AU5005285A (en) 1986-06-12
US4572798A (en) 1986-02-25
EP0185459A3 (en) 1989-02-08
AU594930B2 (en) 1990-03-22
KR860005015A (ko) 1986-07-16
IN163025B (de) 1988-07-30
JPH0696600B2 (ja) 1994-11-30
DE3586987T2 (de) 1993-05-13
KR940003475B1 (ko) 1994-04-22
JPS61140600A (ja) 1986-06-27
DE3586987D1 (de) 1993-02-25
GB2168055B (en) 1988-12-29

Similar Documents

Publication Publication Date Title
DE3586987D1 (de) Methode zur foerderung einer disulfidverbindung in rekombinanten proteinen und formulationen, welche diese produkte enthalten.
US4530787B1 (de)
ES2020498T3 (es) Procedimiento para la activacion de proteinas eucarioticas heterologas, que tienen puentes de disulfuro, preparadas por tecnologia genetica, despues de su expresion en el seno de procariotas.
DE3687763D1 (de) Oxidationsbestaendige il-2-muteine und ihre herstellung, diese muteine enthaltende zusammensetzungen, solche muteine kodierende dns-sequenzen und expressionsvektoren und korrespondierende transformierte wirtzellen.
EP0458959A4 (en) Novel platelet-derived growth factor b chain analogs and method for homogeneous production thereof
DK600688A (da) Polypeptid, dets fremstilling og anvendelse
MY101972A (en) Primate interleukin - 4
ES8603271A1 (es) Un metodo de producir una composicion de interleuquina-2
DK62286A (da) Ikke-antibakterielle tetracyclinpraeparater med anticollagenolytiske egenskaber
DK0646321T3 (da) Dyrefoderadditiv og fremgangsmåde til fremstilling deraf
ATE44235T1 (de) Verwendung von kupfer und fettsaeulen.
TW275066B (de)
ATE72582T1 (de) Oxidationsresistente muteine von beta-interferon, deren herstellung und diese muteine enthaltende praeparate.
FR2635527B1 (fr) Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
ATE101654T1 (de) Verfahren zur gewinnung von mikrobiell hergestelltem beta-interferon.
SE8800990D0 (sv) Skin-regenerating cosmetic compositon and process for preparing same
SE8800988D0 (sv) Pharmaceutical compositons acting on the heart and cardiovascular system and process for preparing same
DE3467340D1 (en) Process for purification of 1,2-unsaturated carboxylic acids and/or esters thereof
Mörikofer-Zwez et al. Heterogeneity of erythrocyte catalase: variability of the isoelectric point
DE69306273D1 (de) Mitogen für die glatte Muskulatur und dessen kodierende DNS
EP0185282A3 (de) Pyridyl-thionophosphorsäureester
SU1591247A1 (ru) Катализатор для окисления сернистых соединений в водно-щелочной среде
Maskos The bifunctional α-amylase/trypsin inhibitor from Ragi: three-dimensional structure, inhibitory properties and oxidative folding in vivo and in vitro
KR890011901A (ko) 동물 성장 촉진제
Khesin et al. Ribonuclease activity in preparations of human leukocyte interferon

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time